The threshold amount of annual net sales of the products.

No definition available.

Name:	obio_AnnualNetSalesThreshold
Namespace Prefix:	obio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of consideration receivable in pursuant to the sale of future revenue interest.

+ References

No definition available.

+ Details

Name:	obio_ConsiderationReceivableFromSaleOfFutureRevenuesInterests
Namespace Prefix:	obio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of tranches in which investment amount shall be paid.

+ References

No definition available.

+ Details

Name:	obio_NumberOfTranches
Namespace Prefix:	obio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of revenue sharing being a Applicable Purchaser Revenue Interest Rate.

+ References

No definition available.

+ Details

Name:	obio_RevenueSharingPercentageApplicablePurchaserRevenueInterestRate
Namespace Prefix:	obio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=obio_RevenueParticipationRightPurchaseAndSaleAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=obio_LigandPharmaceuticalsIncorporatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=obio_AvimTherapyAndVirtueSabProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=obio_TrancheOnePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=obio_TrancheTwoPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=obio_AnnualNetSaleslessThanOrEqualTo100MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=obio_AnnualNetSalesgreaterThanOrEqualTo100MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=obio_LigandStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=obio_LigandWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent Events - Ligand Pharmaceuticals Incorporated Revenue Participation Right Purchase (Details) - Subsequent Events $ / shares in Units, $ in Millions	May 01, 2026 USD ($) shares	Aug. 04, 2025 USD ($) tranche $ / shares shares	Jul. 31, 2025 USD ($) shares
Underwritten public offering
Subsequent Events
Share Price \| $ / shares		$ 2.75
Revenue Participation Right Purchase and Sale Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser")
Subsequent Events
Investment amount			$ 35.0
Revenue Participation Right Purchase and Sale Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Avim Therapy And Virtue Sab Products ("Products")
Subsequent Events
Annual net sales threshold			$ 100.0
Number of tranches \| tranche		2
Revenue Participation Right Purchase and Sale Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Avim Therapy And Virtue Sab Products ("Products") \| Tranche One
Subsequent Events
Investment amount		$ 20.0
Revenue Participation Right Purchase and Sale Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Avim Therapy And Virtue Sab Products ("Products") \| Tranche Two
Subsequent Events
Investment amount	$ 15.0
Revenue Participation Right Purchase and Sale Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Avim Therapy And Virtue Sab Products ("Products") \| Annual Net Sales of the Products less than or equal to $100 million \| Minimum
Subsequent Events
Revenue sharing percentage (%)			17.00%
Revenue Participation Right Purchase and Sale Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Avim Therapy And Virtue Sab Products ("Products") \| Annual Net Sales of the Products less than or equal to $100 million \| Maximum
Subsequent Events
Revenue sharing percentage (%)			20.00%
Revenue Participation Right Purchase and Sale Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Avim Therapy And Virtue Sab Products ("Products") \| Annual Net Sales of the Products greater than or equal to $100 million \| Minimum
Subsequent Events
Revenue sharing percentage (%)			4.00%
Revenue Participation Right Purchase and Sale Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Avim Therapy And Virtue Sab Products ("Products") \| Annual Net Sales of the Products greater than or equal to $100 million \| Maximum
Subsequent Events
Revenue sharing percentage (%)			7.00%
Ligand Stock Purchase Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Underwritten public offering
Subsequent Events
Shares issued (in shares) \| shares		1,818,181
Share Price \| $ / shares		$ 2.75
Value of shares issued			$ 5.0
Ligand Stock Purchase Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Ligand Warrants
Subsequent Events
Exercise Price \| $ / shares		$ 3.67
Warrants expiry term			10 years
Ligand Stock Purchase Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Ligand Warrants \| Maximum
Subsequent Events
Number of warrants to be issued \| shares		2,000,000
Ligand Stock Purchase Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Tranche One \| Ligand Warrants
Subsequent Events
Number of warrants to be issued \| shares			1,142,857
Ligand Stock Purchase Agreement \| Ligand Pharmaceuticals Incorporated (the "Purchaser") \| Tranche Two \| Ligand Warrants
Subsequent Events
Number of warrants to be issued \| shares	857,143